治療用ワクチンの市場規模、シェア、成長分析：製品別、技術別、地域別 - 産業予測 2025年～2032年

治療用ワクチンの世界市場規模は、2023年に537億1,000万米ドルと評価され、2024年の593億5,000万米ドルから2032年には1,319億2,000万米ドルに成長し、予測期間（2025～2032年）のCAGRは10.5％で成長する見通しです。

治療用ワクチン市場は、免疫反応の強化や慢性疾患患者の回復を助けるワクチンへの応用が増加していることから、大きく成長する見通しです。慢性疾患の有病率の上昇に加え、革新的なワクチンの研究開発への投資の増加が売上にプラスの影響を与えると予想されます。さらに、予防ヘルスケアに対する意識の高まりや個別化医療への需要が、今後数年間で治療用ワクチンの採用をさらに後押しすると予想されます。しかし、研究開発の複雑さや有効性の限界に対する懸念といった課題は、市場開拓の妨げになる可能性があります。こうした障害を克服するため、治療用ワクチン企業は、提供する製品をさまざまな免疫療法や精密医療戦略と統合することで相乗効果を探る機会を得ています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

治療用ワクチン市場規模：製品別& CAGR（2025-2032）

• 市場概要
• 依存症ワクチン
• 自己免疫疾患ワクチン
• 感染症ワクチン
• 神経疾患ワクチン

治療用ワクチン市場規模：技術別& CAGR（2025-2032）

• 市場概要
• 自己ワクチン
• 同種ワクチン

治療用ワクチン市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• GlaxoSmithKline plc（GSK）（United Kingdom）
• Sanofi S.A.（France）
• Pfizer Inc.（United States）
• Moderna, Inc.（United States）
• BioNTech SE（Germany）
• Bavarian Nordic A/S（Denmark）
• Medigene AG（Germany）
• Arbutus Biopharma Corporation（Canada）
• Inovio Pharmaceuticals, Inc.（United States）
• Dynavax Technologies Corporation（United States）
• Agenus Inc.（United States）
• Heat Biologics, Inc.（United States）
• Northwest Biotherapeutics, Inc.（United States）
• ImmunoCellular Therapeutics, Ltd.（United States）
• Advaxis, Inc.（United States）
• OncoSec Medical Incorporated（United States）
• Vical Incorporated（United States）
• Celldex Therapeutics, Inc.（United States）
• Altimmune, Inc.（United States）

結論と推奨事項

Global Therapeutic Vaccines Market size was valued at USD 53.71 billion in 2023 and is poised to grow from USD 59.35 billion in 2024 to USD 131.92 billion by 2032, growing at a CAGR of 10.5% during the forecast period (2025-2032).

The therapeutic vaccine market is poised for significant growth, driven by the increasing application of these vaccines in enhancing immune response and aiding recovery in chronic disease patients. The rising prevalence of chronic illnesses, coupled with escalating investments in the research and development of innovative vaccines, is anticipated to positively impact sales. Additionally, the growing awareness of preventive healthcare and the demand for personalized medicine are expected to further boost therapeutic vaccine adoption in the coming years. However, challenges such as the complexity of R&D and concerns over limited efficacy may hinder market development. To navigate these obstacles, therapeutic vaccine companies have the opportunity to explore synergies by integrating their offerings with various immunotherapies and precision medicine strategies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Therapeutic Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Therapeutic Vaccines Market Segments Analysis

Global Therapeutic Vaccines Market is segmented by Products, Technology and Region. Based on Products, the market is segmented into Addiction Vaccines, Autoimmune Disease Vaccines, Infectious Disease Vaccines and Neurological Disease Vaccines. Based on Technology, the market is segmented into Autologous vaccines and Allogeneic vaccines. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Therapeutic Vaccines Market

The rising prevalence of infectious and chronic diseases globally has heightened awareness of the importance of preventive healthcare among the population. This growing consciousness is projected to positively influence the market for therapeutic vaccines, as more individuals recognize the value of vaccination in preventing illness. As a result, the demand for innovative therapeutic vaccine solutions is expected to surge, driving sales and expanding market opportunities. This shift in perspective towards proactive health measures underscores the critical role that therapeutic vaccines play in enhancing public health outcomes and addressing global health challenges.

Restraints in the Global Therapeutic Vaccines Market

The Global Therapeutic Vaccines market faces significant constraints due to the extensive and demanding approval and testing protocols that these vaccines must navigate before being authorized for patient use worldwide. This intricate and time-consuming process can considerably delay the entry of therapeutic vaccines into the market, hindering the overall growth potential of the industry. As a result, the lengthy timeline from development to market availability can create obstacles for companies, stalling innovation and limiting the timely delivery of potentially life-saving treatments to patients in need across the globe.

Market Trends of the Global Therapeutic Vaccines Market

The Global Therapeutic Vaccines market is witnessing a significant shift towards the integration of vaccines within immunotherapy frameworks, aimed at enhancing treatment efficacy for cancer patients. Vendors are increasingly focusing on developing innovative products that tailor immune responses to specific tumor types, thereby optimizing therapeutic outcomes. This trend reflects a growing recognition of the importance of personalized immunotherapy, where therapeutic vaccines are designed to modify and strengthen the body's immune system against cancer more effectively. As research and clinical applications advance, this strategic alignment is expected to drive substantial growth in the therapeutic vaccines sector, positioning it as a key component in the fight against cancer.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Therapeutic Vaccines Market Size by Products & CAGR (2025-2032)

• Market Overview
• Addiction Vaccines
• Autoimmune Disease Vaccines
• Infectious Disease Vaccines
• Neurological Disease Vaccines

Global Therapeutic Vaccines Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Autologous vaccines
• Allogeneic vaccines

Global Therapeutic Vaccines Market Size & CAGR (2025-2032)

• North America (Products, Technology)
  • US
  • Canada
• Europe (Products, Technology)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Products, Technology)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Products, Technology)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Products, Technology)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• GlaxoSmithKline plc (GSK) (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bavarian Nordic A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medigene AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arbutus Biopharma Corporation (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inovio Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dynavax Technologies Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agenus Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Heat Biologics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Northwest Biotherapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ImmunoCellular Therapeutics, Ltd. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Advaxis, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OncoSec Medical Incorporated (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vical Incorporated (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celldex Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Altimmune, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations